The introduction of amivantamab presents a significant step forward for patients battling cancers exhibiting c-MET overexpression. This innovative antibody, a precise agent of multiple MET kinase plus human epidermal growth factor receptor 2 (HER2), showed early efficacy in research assessments, particularly in individuals whose tumors display meas